Gfp: I expect that some mention will be made regarding the closure of the open file with Neurology--either as part of an IND PR (if they are close in time) or on its own. It's barely material--unless the FDA throws a curve, which can happen, though I consider it unlikely.
"Clean bill of health": I have several times stated that it is my opinion that the FDA, in this current hyperconservative regulatory climate, would not have permitted resumption of higher dosing of CX717 if it continued to have concerns regarding safety. It's my conclusion from reading the tea leaves, which in fact is what companies dealing with the FDA have to do all the time. I have no problem with the concept that others may formulate different opinions. But Those who want the clarity and certainty of adherence to formalized written agreements are not likely to find it in the drug/biotech sector. That's why the risk/reward dynamic is so huge, on both sides.
Blade: <<No Neuro, I'm not asking you to write your Congressman. I'm just asking to you treat Stoll like something other than your bed partner.>>
Just because you had yet another stock turn against you does not justify your taking it out on me. I don't make the rules (or the FDA's refusal to play by them). If there are questions you want asked of Cortex on a CC, you call in and ask them. If you don't, don't blame anyone else, it will be your own cojones that will be in question.
NeuroInvestment
Market Data 
Markets 
AI
